Tag: OmniPod

ACTON, Mass. – Insulet has received U.S. Food and Drug Administration clearance for its Omnipod 5 Automated Insulin Delivery System for individuals aged two years and older with Type 1 diabetes. “We received tremendous first-hand reports of how Omnipod 5 made diabetes management easier for our pivotal trial participants, and the clinical data demonstrated impressive glycemic improvements, as well,” said Dr. Trang Ly, MBBS, FRACP, PhD, Insulet’s senior vice president and medical...

ACTON, Mass. – Insulet Corporation reported revenue of $307.7 million for the fourth quarter of 2021, and full year revenue of $1.1 billion. Total Omnipod revenue was $275.8 million for the quarter and $1 billion for the full year. Of that, U.S. Omnipod revenue for the year was $651.5 million and international Omnipod revenue of $359.9 million. “2021 was another successful year for Insulet, as we reached an important milestone of over $1 billion in revenue and advanced our strategic priorities,”...

ACTON, Mass. – Insulet Corp. reported revenue of $275.6 million for the third quarter of 2021, up 17.8% over the same period last year.  It reported revenue was $260.3 million, up 22.7%, for Omnipod.  "Our third quarter results reflect the growing power of Omnipod,” said Shacey Petrovic, president and CEO. “We are driving global new customer starts, have momentum across our business, and are advancing exciting new innovations. We continue to share compelling clinical...

ACTON, Mass. – Insulet  reported revenues of $246.1 million for the fourth quarter of 2020, an increase of 17.5% over the same quarter in 2019. Full-year revenues were $904.4 million, an increase of 22.5% compared to the previous year. For the quarter, U.S. Omnipod revenue was $231.1 million and International Omnipod revenue was $149.2 million. Omnipod revenue for the full year was $834.9 million: $526.9 million in U.S. Omnipod...

ACTON, Mass. - Insulet, maker of the OmniPod system, has expanded its U.S. financial assistance program for current customers who have been negatively impacted by COVID-19. Upon meeting certain financial criteria, those customers may receive up to a six-month supply (60 pods). “Our coronavirus response plan is guided by our fundamental principles of protecting the health and safety of our employees, preserving the well-being of the communities in which we live and work, and ensuring that customers...

ACTON, Mass. - Insulet Corp. reported revenue of $738.2 million for 2019, a 31% increase compared to 2018. The company reported full-year revenue of $673.5 million for the Omnipod, broken down by U.S. revenue of $420.2 million and international revenue of $253.1 million, a 30% and 47% increase, respectively.Insulet reported revenue of $209.4 million for the fourth quarter of 2019, a 27% increase compared to the same period in 2018. Operating income was $18.2 million."2019 was a remarkable year for...

ACTON, Mass. - Insulet Corp. has reported net income of $9.9 million for the fourth quarter of 2018 compared to a net loss of $6.9 million for the same period in 2017.The company reported net income of $3.3 million for all of 2018 vs. a net loss of $26.8 million for 2017.It's the first time in Insulet's history that the company has achieved full-year positive operating income and net income.“Insulet had a remarkable 2018, achieving our third consecutive year of over 20% revenue growth, significantly...

BILLERICA, Mass. - Insulet Corp., maker of the Omnipod Insulin Management System, reported revenues of $124.3 million for the second quarter, a 13% increase compared to the same period last year. It reported revenues of $78.1 million for the Omnipod in the U.S., a 19% increase. Insulet reported a net loss of $1.7 million for the second quarter compared to a net loss of $7.8 million for the same period last year. Among the company's highlights in the second quarter: It assumed direct European operations...

BILLERICA, Mass. - Insulet Corp. reported revenue of $130.5 million for the fourth quarter of 2017, an increase of 26% compared to the same period in 2016. U.S. revenue from the Omnipod was $76.5 million, an increase of 21%. Full-year revenue was $463.8 million and U.S. revenue from the Omnipod was $271.6 million. Among Insulet's highlights for 2017: It received Medicare coverage under the prescription drug benefit for the Omnipod, paving the way to capturing an additional one-third of the U.S. market;...

BILLERICA, Mass. - Insulet Corp. reported revenues of $121.8 million for the third quarter of 2017, representing year-over-year growth of 28%. Net loss was 2.2 million. For the Omnipod, revenues in the U.S. were $70.1 million for the quarter, a 17% increase, and, internationally, $32.5 million, a 70% increase. Revenue from drug delivery was $19.2 million, a 19% increase. “We achieved strong third quarter results across all of our businesses, particularly in our international business,”...